Alliancebernstein L.P. Has $17.73 Million Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Alliancebernstein L.P. cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 27.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 733,367 shares of the company’s stock after selling 283,287 shares during the quarter. Alliancebernstein L.P.’s holdings in Hims & Hers Health were worth $17,733,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. SlateStone Wealth LLC lifted its stake in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after purchasing an additional 413 shares during the last quarter. Blume Capital Management Inc. lifted its position in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after buying an additional 600 shares during the last quarter. Harbour Investments Inc. boosted its stake in shares of Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock worth $127,000 after acquiring an additional 833 shares in the last quarter. Stonekeep Investments LLC increased its holdings in shares of Hims & Hers Health by 5.5% during the 4th quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after acquiring an additional 882 shares during the last quarter. Finally, LPL Financial LLC raised its stake in shares of Hims & Hers Health by 1.0% in the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company’s stock valued at $2,369,000 after acquiring an additional 980 shares in the last quarter. 63.52% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on HIMS. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price on the stock. Leerink Partners raised their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Needham & Company LLC raised their target price on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Finally, Citigroup reiterated a “sell” rating on shares of Hims & Hers Health in a report on Wednesday, April 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Trading Down 6.3 %

HIMS opened at $26.02 on Wednesday. The stock’s 50 day simple moving average is $39.53 and its 200-day simple moving average is $30.15. The stock has a market cap of $5.78 billion, a PE ratio of 59.14 and a beta of 1.65. Hims & Hers Health, Inc. has a 1 year low of $11.20 and a 1 year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total transaction of $174,724.13. Following the transaction, the insider now directly owns 193,601 shares of the company’s stock, valued at $4,659,976.07. This represents a 3.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 809,806 shares of company stock worth $30,923,658 over the last quarter. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.